United States: FTC's Amicus Brief In Wellbutrin XL Appeal Highlights Significance For Interpretation Of Actavis

The FTC has recently weighed in again on the evolving interpretation of the Supreme Court's 2013 opinion in FTC v. Actavis, 133 S. Ct. 2223 (2013). The agency submitted an amicus brief to the Third Circuit in the appeal of the district court's September 2015 grant of summary judgment in In re Wellbutrin XL Antitrust Litigation, — F. Supp. 3d —- (E.D. Pa. Sept. 23, 2015) ("Wellbutrin XL").

In Wellbutrin XL, direct and indirect purchaser plaintiffs brought antitrust claims against GlaxoSmithKline ("GSK"), the manufacturer of the antidepressant drug Wellbutrin XL, and Biovail, which owns rights to related patents (collectively, "Biovail"), in connection with Biovail's alleged "reverse payment" settlement of patent litigation with generic competitors that allegedly delayed the market entry of a generic version of the drug.

In its simplest form, a "reverse payment" settlement involves a payment from a brand-name drugmaker plaintiff to a generic competitor defendant to settle Hatch-Waxman Act patent infringement litigation in exchange for an agreement by that defendant not to launch a competing generic version of the drug until some time in the future. In its 2013 Actavis opinion, the Supreme Court held that such a "reverse payment" – if "large" and "unexplained" – may raise antitrust issues because it suggests that the brand-name company has doubts about the viability of its patents and is therefore paying the generic competitor to drop its challenge to those patents. Under the Hatch-Waxman scheme, this can prevent generic entry into the market altogether and preserve the branded company's monopoly profits.

The agreement at issue in Wellbutrin XL differed from this prototypical reverse payment scenario because it did not, as a technical matter, settle the underlying patent litigation. Rather, in Wellbutrin XL, the generic defendant in the underlying patent action, Anchen, had already prevailed in the district court, had been involved in the "at risk" launch of 300-mg generic Wellbutrin XL while the matter was on appeal (i.e., at risk of a sizable damages judgment because the patent infringement action was not final), and planned to launch a 150 mg generic version of the drug in early 2007. The parties then agreed that Anchen would hold off on launching the generic 150 mg version for over a year unless the appeal was resolved in its favor before that time. The agreement also included a "no-AG" (i.e., no authorized generic) agreement under which GSK would not launch its own competing "authorized generic" during the 180-day "first-filer exclusivity" period granted to Anchen under the Hatch-Waxman scheme.

On summary judgment, the district court in Wellbutrin XL dismissed the antitrust claims, finding that no reasonable jury could find the challenged agreement to be unlawful, and the plaintiffs appealed that ruling to the Third Circuit. In its brief, while officially taking no position on the merits of the case, the FTC points out what it characterizes as "fundamental legal errors" in the district court's analysis. Perhaps most importantly, the FTC contends that the district court applied an "untenably narrow" reading of Actavis, finding that it applied only when a reverse payment causes a generic challenger to abandon its patent challenge altogether. According to the FTC, Actavis teaches that a reverse payment may be anticompetitive and raise antitrust concerns whenever it induces the generic company to stay out of the branded drug's monopoly market, regardless of whether the underlying patent litigation continues. In Wellbutrin XL, the FTC claims, the generic competitor could have launched "at risk" following its district court victory, but agreed to delay market entry in exchange for a no-AG agreement from Biovail valued at $200 million. In finding Actavis inapplicable simply because the underlying litigation was not ended, the district court improperly "elevated nominal factual distinctions over economic reality."

A closer look at the case reveals a more nuanced picture, however. The district court observed that the settlement at issue did not present the same antitrust concerns as those motivating the Actavis decision. However, the court recognized that an overly formalistic reading of Actavis risked creating an "easily exploited loophole," and proceeded to analyze the settlement under the rule-of-reason, as Actavis instructs. The court stated, however, that the parties' preservation of the underlying patent litigation is a "factor to be considered" in the analysis, suggesting that the court applied a modified version of the rule-of-reason test. It is not clear that this approach is inappropriate, though, since the rule-of-reason test is notoriously fact-specific, and the Actavis opinion expressly recognized that the proof required would vary with the circumstances.

Wellbutrin XL involves a complex settlement agreement with many interconnected components, reached in an equally complicated factual context. For example, Anchen faced regulatory obstacles to launching, an uncertain prospect of prevailing on appeal, plus potential liability for "at risk" launch in a separate patent infringement action brought by a third party – the defense of which was complicated by potential estoppel issues because Anchen's CEO was the inventor on the patent-in-suit. The settlement with Biovail included patent licenses that removed an important obstacle to the generic launch. The FTC's brief glosses over much of this complexity. In the FTC's view, however, there is a potential antitrust violation (though perhaps not private-party standing) when there is an unexplained reverse payment – here in the form of a no-AG agreement – and delayed entry, suggesting the sharing of monopoly profits in exchange for an agreement to preserve that monopoly, at least for a time. Any procompetitive benefits must be linked to the reverse payment to be considered.

The FTC's brief raises critical questions regarding the meaning of Actavis and its application to Hatch-Waxman settlement agreements that depart from the "classic" reverse-payment structure. The Third Circuit's resolution of these issues in the Wellbutrin XL appeal may be a significant step in further defining the contours of Actavis and helping parties to craft settlement agreements that actually achieve settlement, rather than more litigation.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Sheppard Mullin Richter & Hampton
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Sheppard Mullin Richter & Hampton
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions